P-glycoprotein Expression in Breast Cancer
Author Information
Author(s): A.R. Dixon, J. Bell, I.O. Ellis, C.W. Elston, R.W. Blamey
Primary Institution: City Hospital, Nottingham, UK
Hypothesis
Can P-glycoprotein expression be used to identify patients who may avoid multidrug resistance chemotherapy in breast cancer?
Conclusion
The study found no clear clinical utility for P-glycoprotein expression in identifying patients who could avoid multidrug resistance chemotherapy.
Supporting Evidence
- Twelve tumors exhibited an objective response to the chemotherapy.
- None of the 26 primary tumors studied stained clearly positive for P-glycoprotein.
- Small amounts of weak stromal staining were observed in two tumors treated by tamoxifen.
Takeaway
The researchers looked at a protein called P-glycoprotein in breast cancer to see if it could help doctors choose better treatments, but they didn't find it useful.
Methodology
The study used immunohistochemistry to investigate P-glycoprotein expression in tumor samples from patients treated with chemotherapy.
Limitations
The study had a small sample size and did not demonstrate a clear role for P-glycoprotein in drug resistance in vivo.
Participant Demographics
Twenty-four women with locally advanced primary breast cancer.
Want to read the original?
Access the complete publication on the publisher's website